Science
Waisman Biomanufacturing partners with GigaGen to manufacture new COVID-19 drug – Mirage News
Waisman Biomanufacturing at the University of Wisconsin-Madison will begin manufacturing a new drug to treat and prevent COVID-19, developed by…
Waisman Biomanufacturing at the University of Wisconsin-Madison will begin manufacturing a new drug to treat and prevent COVID-19, developed by California-based biotech company GigaGen.
The drug, called GIGA-2050, uses a new approach similar to treating COVID-19 patients with convalescent plasma, or blood products from people recovering (convalescing) from an infection. Waisman Biomanufacturing was created to facilitate just this sort of development and testing of new types of drugs.
“Our miss…
-
Noosa News14 hours agoMega-team of heavy horses sets world record at Good Old Days Festival
-
General18 hours agoEnglish springer spaniels Kelly and Milo helping fight dieback in Western Australia
-
General7 hours agoHow the internet reacted to Brisbane Broncos winning the NRL grand final
-
Business23 hours agoTop brokers name 3 ASX shares to buy next week 5 October 2025